Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Recurring Glioblastoma: A Case for Reoperation?.

Dejaegher J, De Vleeschouwer S.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 14.

2.

Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.

Belmans J, Van Woensel M, Creyns B, Dejaegher J, Bullens DM, Van Gool SW.

Sci Rep. 2017 Oct 24;7(1):13902. doi: 10.1038/s41598-017-12584-0.

3.

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.

Mathivet T, Bouleti C, Van Woensel M, Stanchi F, Verschuere T, Phng LK, Dejaegher J, Balcer M, Matsumoto K, Georgieva PB, Belmans J, Sciot R, Stockmann C, Mazzone M, De Vleeschouwer S, Gerhardt H.

EMBO Mol Med. 2017 Dec;9(12):1629-1645. doi: 10.15252/emmm.201607445.

4.

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.

Dejaegher J, Verschuere T, Vercalsteren E, Boon L, Cremer J, Sciot R, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2017 Nov 1;141(9):1891-1900. doi: 10.1002/ijc.30877. Epub 2017 Jul 19.

PMID:
28681455
5.

10-year follow-up after implantation of the Bryan Cervical Disc Prosthesis.

Dejaegher J, Walraevens J, van Loon J, Van Calenbergh F, Demaerel P, Goffin J.

Eur Spine J. 2017 Apr;26(4):1191-1198. doi: 10.1007/s00586-016-4897-2. Epub 2016 Nov 30.

PMID:
27904963
6.

Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Dejaegher J, Van Gool S, De Vleeschouwer S.

Immunotargets Ther. 2014 Mar 13;3:55-66. doi: 10.2147/ITT.S40121. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center